ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) Sees Large Increase in Short Interest

ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) saw a large increase in short interest in June. As of June 15th, there was short interest totalling 35,000 shares, an increase of 797.4% from the May 31st total of 3,900 shares. Approximately 4.2% of the shares of the stock are short sold. Based on an average trading volume of 207,400 shares, the days-to-cover ratio is currently 0.2 days.

ZyVersa Therapeutics Stock Up 3.9 %

Shares of ZVSA opened at $3.76 on Friday. ZyVersa Therapeutics has a 12 month low of $3.41 and a 12 month high of $115.15. The stock’s 50-day moving average price is $4.88 and its two-hundred day moving average price is $6.62.

ZyVersa Therapeutics (NASDAQ:ZVSA) last announced its earnings results on Wednesday, May 15th. The company reported ($4.53) EPS for the quarter, missing the consensus estimate of ($3.70) by ($0.83). As a group, research analysts anticipate that ZyVersa Therapeutics will post -15.05 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and set a $120.00 price objective on shares of ZyVersa Therapeutics in a report on Tuesday, March 26th.

ZyVersa Therapeutics Company Profile

ZyVersa Therapeutics, Inc, a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity.